Drugs /

pegylated interferon alfa

Back to Drugs List

Overview

NCI Definition [1]:
A covalent conjugate of recombinant interferon alpha and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)

Clinical Trials

View Clinical Trials for pegylated interferon alfa

Pegylated interferon alfa has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating pegylated interferon alfa, 2 are phase 3 (2 open).

BCR-ABL1 Fusion and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for pegylated interferon alfa clinical trials.

Chronic myeloid leukemia is the most common disease being investigated in pegylated interferon alfa clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pegylated Interferon Alfa
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pegylated interferon alfa and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
peg-ifn-a, peg-interferon alfa, peg-ifna
Drug Target(s) [2]:
IFNAR1, IFNAR2
NCIT ID [1]:
C2491

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.